Chris Roberts jumps back in­to biotech with CSO gig at Black Di­a­mond; Trou­bled Five Prime ap­points in­ter­im CEO

→ Af­ter spend­ing two years as en­tre­pre­neur-in-res­i­dence at SR One — the ven­ture arm of his for­mer em­ploy­er, Glax­o­SmithK­line — Chris Roberts is back at the front­lines of biotech.

As CSO of Black Di­a­mond Ther­a­peu­tics, Roberts joins CEO David Ep­stein in dri­ving their tar­get­ed ki­nase in­hibitors to­ward the clin­ic. He will lead re­search and ear­ly de­vel­op­ment on the biotech’s MAP plat­form, which ze­roes in on al­losteric mu­ta­tions of onco­genes. Its lead can­di­date, BDTX-189, tar­gets EGFR and HER2 re­gard­less of tu­mor type.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN